The PennZone

  • Home
  • Business
  • Health
  • Education
  • Financial
  • Entertainment
  • Legal
  • Construction
  • Music

Viatris Wins Court Decisions on Sanofi Appeals of Lantus® Patent Invalidations
The PennZone/10160194

Trending...
  • Big Butler Fair Announces 2025 Music Lineup and Grandstand Events
  • Make Innovation Matter: Support H.R.1's R&D Expensing Relief for American Small Businesses
  • VIP Vacations Recognized as a Top 50 Producer with Pleasant Holidays
PITTSBURGH, Dec. 29, 2021 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) announced that it is pleased with decisions issued today which affirm the U.S. Patent and Trademark Appeal Board's prior rulings that found the challenged claims of Sanofi's Lantus® SoloSTAR® device patents, U.S. Patent Nos. 9,603,044, 8,992,486, 9,526,844, 9,604,008, and 8,679,069, unpatentable.

These affirmances reinforce the company's continuing efforts to break down barriers to patient access for important medicines such as Semglee® through its Global Healthcare Gateway®. Viatris and Biocon Biologics Ltd. launched their interchangeable Semglee® products (insulin glargine-yfgn) last month, which are the first, and currently the only, interchangeable biosimilars to Lantus®, providing more affordable options for the millions of Americans living with diabetes.

The Semglee® products are available in vial and prefilled pen presentations and are interchangeable for the reference brand, Lantus®, allowing for substitution at the pharmacy counter.  Semglee® is indicated to help control high blood sugar in adult and pediatric patients with type 1 diabetes and adults with type 2 diabetes.

About Viatris
Viatris Inc. (NASDAQ: VTRS) is a new kind of healthcare company, empowering people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to connect more people to more products and services through our one-of-a-kind Global Healthcare Gateway®. Formed in November 2020, Viatris brings together scientific, manufacturing and distribution expertise with proven regulatory, medical and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. Viatris' portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized brands, complex generic and branded medicines, a growing portfolio of biosimilars and a variety of over-the-counter consumer products. With a global workforce of approximately 38,000, Viatris is headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at viatris.com and investor.viatris.com, and connect with us on Twitter at @ViatrisInc, LinkedIn and YouTube.

More on The PennZone
  • The AML Shop Launches New Financial Investigations Unit, Appoints Director to Lead the Initiative
  • Casting Pro Darya Balyura Named Judge for 2025 Meals 4 Monologues Virtual Showcase
  • Raidium révolutionne le diagnostic de la Sclérose en Plaques en partenariat avec l'Hôpital Fondation Adolphe de Rothschild
  • New Podcast "Spreading the Good BUZZ" Hosted by Josh and Heidi Case Launches July 7th with Explosive Global Reach and a Mission to Transform Lives
  • The Herbal Care, Led by Markel Bababekov, Becomes a Top Dispensary in NYC's Upper East Side

Forward-Looking Statements
This press release includes statements that constitute "forward-looking statements." These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward looking statements may include statements about the outcome and status of ongoing litigation. Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such statements. Factors that could cause or contribute to such differences include, but are not limited to: the scope, timing and outcome of any ongoing legal proceedings and the impact of any such proceedings; that court decisions are not yet final and are subject to further review, rehearing and appeal, which could result in an adverse outcome; the potential impact of public health outbreaks, epidemics and pandemics, including the ongoing challenges and uncertainties posed by the COVID-19 pandemic; the integration of Mylan N.V. and Pfizer Inc.'s Upjohn business (the "Upjohn Business"), which combined to form Viatris (the "Combination") and the implementation of our global restructuring initiatives being more difficult, time consuming or costly than expected, or being unsuccessful; the ability to achieve expected benefits, synergies and operating efficiencies in connection with the Combination or its restructuring initiatives within the expected timeframe or at all; actions and decisions of healthcare and pharmaceutical regulators; changes in healthcare and pharmaceutical laws and regulations in the U.S. and abroad; any regulatory, legal or other impediments to Viatris' ability to bring new products to market, including but not limited to "at-risk" launches; Viatris' or its partners' ability to develop, manufacture and commercialize products; any significant breach of data security or data privacy or disruptions to our information technology systems; risks associated with international operations, including our operations in China; the ability to protect intellectual property and preserve intellectual property rights; changes in third-party relationships; the effect of any changes in Viatris' or its partners' customer and supplier relationships and customer purchasing patterns; the impacts of competition; changes in the economic and financial conditions of Viatris or its partners; uncertainties and matters beyond the control of management; and the other risks Viatris' filings with the Securities and Exchange Commission. Viatris routinely uses its website as a means of disclosing material information to the public in a broad, non-exclusionary manner for purposes of the SEC's Regulation Fair Disclosure (Reg FD). Viatris undertakes no obligation to update these statements for revisions or changes after the date of this release other than as required by law.

More on The PennZone
  • Digital Watchdog Launches New myDW Cloud Services
  • Stan Fitzgerald Appointed Acting Press Secretary for Veterans for America First VFAF Georgia State Chapter
  • Drone Light Shows Emerge as the New Standard in Live Event Entertainment
  • Lore Link is Here to Help Organize Your Game
  • Chappaqua's Annual Townwide Summer Sale – Unbeatable Savings at Your Favorite Local Boutiques!

SOURCE Viatris Inc.
Filed Under: Business

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Valley Sleep Therapy Expands to Prescott with New Location at Crossings Road
  • $17.4 Million Total Revenue for First Half of 2025 (up 31.8% YOY) for Global Wet Trades Services Provider with High Value Bitcoin Investments
  • $12.8 Million Net Revenue for 2024 for Cloud-Based Crowdsourcing Recruitment and SaaS-Enabled HR Solutions Provider: Baiya International Group Inc
  • #ChipInChipAway at Hunger Taking Place on July 10th, 2025
  • Hire Virtue Announces Executive Sponsorship Opportunity for Houston Hiring Blitz & Job Fair on August 6, 2025
  • Inked & Maxim Model Teisha Mechetti Turns Heads—And Builds Community Impact
  • Plan to Launch Silo Technologies' Cybersecurity Pilot Program for Ultimate Nationwide Deployment via Exclusive Partnership: Stock Symbol: BULT
  • Robert Michael & Co. Real Estate Team Celebrates Industry Recognition and Showcases Premier Central Florida Listings
  • INVESTIGATION ALERT: Berger Montague PC Investigates Aflac, Inc.'s Board Of Directors For Breach of Fiduciary Duties (NYSE: AFL)
  • AI-Based Neurotoxin Countermeasure Initiative Launched to Address Emerging National Security Needs: Renovaro, Inc. (N A S D A Q: RENB)
  • The Naturist World Just Shifted — NaturismRE Ignites a Global Resurgence
  • $796,000 in Q2 Revenue Marks Highest Earnings to Date on 3 Trailing Quarters of Profitability in Multi-Billion Homebuilding Sector: Stock Symbol: IVDN
  • Cybersecurity is THE Hot Market Sector; Revenues, Earnings & Profit matter; Only 33 Million Shares + a Huge Short Position Equal an Undervalued Stock
  • Despite Global Calls for a Ban, US Child Psychiatry Pushes Electroshock for Kids
  • BeyondTrucks CEO Wins Gold Stevie® Award for Best Entrepreneur in Transportation
  • Franco Polished Plaster Celebrates 35 Years of Bringing Walls to Life in the UK
  • Spartan & Guardians Partner with Guitar Legend Buckethead to Support Global Child Rescue Efforts
  • C8C.AI Launches Audio Compliance Engine to Streamline Ethical AI Audio Data at Scale
  • Preliminary.online Introduces Short-Term Job-Readiness Courses with Employer-Verified Certifications
  • Psychologist-Turned-Hermeticist Releases Modern Guide to the Seven Hermetic Principles

Popular on PennZone

  • AI in Healthcare Just Crossed a Tipping Point. Investors Are Watching These Names - 180
  • Real Estate CEO Launches Explosive New Book After $275,784 Wire Fraud Incident
  • Kaplan Morrell Applauds Passage of Landmark Workers' Compensation Reform in Colorado
  • Western Carolina Emergency Network Accepts 2025 ReadyCommunities Partnership/CCROA National Service Award for Collaboration to Augment Local Response
  • JMC Princess Announces Release of Empowering New Single "PRETTY" – A Summer Anthem for Young Girls Everywhere
  • Conexwest Unveils 20ft Ground-Level Mobile Office Container with Integrated Restroom
  • The World's No.1 Superstar™ Silences His Own Husband with Legally Binding NDA — "Call Him Mr. Sidow Sobrino" Now Law
  • Rediscovered Christopher Lee Recording 'Elenore' Re-Released to Mark 10th Anniversary of His Passing
  • TEDxInglewood Returns to The Miracle Theater on August 9, 2025 — Celebrating Bold Ideas and Community Energy
  • Manhattan Boutique Real Estate Collaborates with InterContinental Hotels NYC in a Branding Partners Personalized Approach

Similar on PennZone

  • Real Estate Experts Highlight Jersey Shore as a Smart Buy in 2025
  • $18 Price Target Issued in New Research Report After $34 Million Revenue Forecast from Acquisition; $101.5 Million Net Revenue in 2025; NAS DAQ: IQST
  • The AML Shop Launches New Financial Investigations Unit, Appoints Director to Lead the Initiative
  • New Podcast "Spreading the Good BUZZ" Hosted by Josh and Heidi Case Launches July 7th with Explosive Global Reach and a Mission to Transform Lives
  • Drone Light Shows Emerge as the New Standard in Live Event Entertainment
  • Skyline Partners with ZenSpace to Offer Private Meeting Pods for Trade Show Exhibitors
  • DICK'S Sporting Goods Announces DICK'S Deal Days, a Four-Day Summer Savings Event
  • AI Innovation Dual-Strategy Business Model Focused on Real Estate Development for Strategic Expansion: OFA Group, (N A S D A Q: OFAL)
  • Berger Montague Investigates Securities Class Action Against Hims & Hers Health Inc. (NYSE: HIMS)
  • Valley Sleep Therapy Expands to Prescott with New Location at Crossings Road
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us